Clinical trials: Luminal B Breast Cancer
Breast Cancer, HER2-negative Breast Cancer
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
Patients with locally advanced (stage III) breast cancer (LABC) are characterized by a significantly worse prognosis compared to patients with primarily operable breast cancer.
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Locally Advanced Breast Cancer
- Trial name
- NEOLETRIB (NCT05163106)
- Testing
- Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet, Goserelin
- Where
- Norway
- Volunteers
- 85 people
- Sponsor
- University Hospital, Akershus
Luminal B
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Neo-CheckRay is a multicenter, open-label phase II study that randomizes luminal B breast cancer subjects candidate for neo-adjuvant chemotherapy in a 1:1:1 ratio in 3 arms: 1.
- Trial name
- Neo-CheckRay (NCT03875573)
- Testing
- Durvalumab, Stereotactic Body Radiotherapy, Oleclumab
- Where
- 7 sites in Belgium, France
- Volunteers
- 147 people
- Sponsor
- Jules Bordet Institute
Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases
The purpose of this neoadjuvant trial is to evaluate efficacy and toxicity of chemotherapy using weekly paclitaxel (arm A) versus the combination of the cdk 4/6 inhibitor palbociclib and standard endocrine treatment (arm B).
- Trial name
- PREDIX LumB (NCT02603679)
- Testing
- Paclitaxel, Tamoxifen + Palbociclib, Aromatase Inhibitor + Palbociclib
- Where
- 3 sites in Sweden
- Volunteers
- 181 people
- Sponsor
- Thomas Hatschek
Breast Cancer, Sentinel Lymph Node Biopsy
Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents
This clinical trial is designed as an observational study of 8-9 years of overall duration, but the first results and conclusions could be achieved in 3-4 years.
- Conditions
- Breast Cancer, Sentinel Lymph Node Biopsy, Neoadjuvant Chemotherapy
- Trial name
- NCT03719833
- Where
- Croatia
- Volunteers
- 230 people
- Sponsor
- Clinical Hospital Center Rijeka
Metastatic Uveal Melanoma, Triple Negative Breast Cancer
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)
Resistance to treatment is one of the major themes in cancer research. Despite this, the definition and clinical implications of resistance to treatment remain under-explored, and patient-physician communication in this context…
- Conditions
- Metastatic Uveal Melanoma, Triple Negative Breast Cancer, Luminal B Breast Cancer, Pediatric Cancer
- Trial name
- NCT04118062
- Testing
- Questionnaires, Semi-structured individual interviews, Focus Group
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Institut Curie
Breast Cancer, Triple Negative Breast Cancer
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
The study has a phase Ib and a phase II part. The phase Ib aims to evaluate the safety and tolerability of durvalumab in combination with a dose- dense EC regimen in a neoadjuvant setting for early breast cancer.
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Luminal B
- Trial name
- B-IMMUNE (NCT03356860)
- Testing
- Paclitaxel, Epirubicin, Cyclophosphamide
- Where
- 4 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Grand Hôpital de Charleroi
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients
Human epidermalgrowth factor receptor-2(HER2) negative Luminal B subtype breast cancer patients are included. After 4 cycles of Capecitabine combined with Docetaxel(XT) protocol neoadjuvant chemotherapy ,those who reach partial…
- Trial name
- NCT01779531
- Where
- China
- Volunteers
- 640 people
- Sponsor
- Guangdong Academy of Medical Sciences
Radiation Therapy, Breast Cancer, Sequential Partial Breast Irradiation, Intermediate and High-risk Luminal and Triple Negative Breast Cancer
Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone
In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC.
- Trial name
- Néo-APBI-01 (NCT02806258)
- Testing
- Accelerated partial breast irradiation, Chemotherapy
- Where
- 6 sites in France
- Volunteers
- 362 people
- Sponsor
- University Hospital, Grenoble
Breast Cancer
Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
This is a prospective, non-randomized, open-label, multicenter, single-arm exploratory pharmacogenomic study of single agent eribulin as neoadjuvant therapy in patients with operable Stage III HER2 non-overexpressing breast…
- Trial name
- NeoEribulin (NCT01669252)
- Testing
- Eribulin
- Where
- 30 sites in France, Germany and 2 more
- Volunteers
- 163 people
- Sponsor
- SOLTI Breast Cancer Research Group
Primary Breast Cancer
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
We aimed to evaluate the noninferiority of short-term anthracycline-free chemotherapy (TC, six cycles of docetaxel and cyclophosphamide) or short-term anthracycline-based chemotherapy (CEF-T, three cycles of…
- Trial name
- NCT01314833
- Testing
- Docetaxel Cyclophosphamide, Cyclophosphamide Fluorouracil Epirubicin Docetaxel, Epirubicin Cyclophosphamide Paclitaxel
- Where
- China
- Volunteers
- 1,570 people
- Sponsor
- Fudan University
Breast Cancer
Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes
This is a translational study in patients with operated early breast cancer of Luminal A or Luminal B sub types.The Hellenic Cooperative Oncology Group (HeCOG) has designed an observational biomarker-driven study in patients with…
- Trial name
- NCT04403984
- Where
- Greece
- Volunteers
- 750 people
- Sponsor
- Hellenic Cooperative Oncology Group
Breast Cancer
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
Multicentric, phase II neoadjuvant trial in hormone-positive, HER-negative, luminal B, premenopausal breast cancer patients stage II-IIIA.
- Trial name
- GIADA (NCT04659551)
- Testing
- Epirubicin, Cyclophosphamide, Triptorelin
- Where
- 5 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Breast Cancer
Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study)
PhActHealth is a multicenter randomized controlled trial enrolling women with newly diagnosed luminal B or triple-negative breast cancer (BC) who are candidates for neoadjuvant therapy.
- Trial name
- PhActHealth (NCT07776951)
- Testing
- Pre-habilitation exercise program
- Where
- 2 sites in Italy
- Volunteers
- 126 people
- Sponsor
- University of Milan
Primary Breast Cancer
Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)
Cabazitaxel is a new taxoid which promotes the tubulin assembly in vitro and stabilizes microtubules against cold-induced depolymerization as efficiently as docetaxel and was selected for development based on a better…
- Trial name
- NCT01779479
- Testing
- Cabacitaxel, Paclitaxel
- Where
- Germany
- Volunteers
- 333 people
- Sponsor
- GBG Forschungs GmbH